Why Heartbeam Shares Are Skyrocketing 75% Higher
Why Heartbeam Shares Are Skyrocketing 75% Higher
$HeartBeam (BEAT.US)$ shares are trading higher by 76% to $2.20 Thursday morning after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome and cardiac arrhythmia was issued by the USPTO.
$HeartBeam (BEAT.US)$週四上午，該公司股價上漲76%，至2.20美元，此前該公司宣佈，美國專利商標局發佈了用於檢測急性冠脈綜合徵和心律失常的12導聯心電貼片監測器的專利。
Heartbeam says this builds on the company's growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting.
哈特伯姆表示，這是建立在該公司不斷增長的知識產權組合的基礎上的，該組合能夠在醫療環境之外實現12導聯心電診斷。
"This patent provides additional intellectual property protection for our breakthrough ECG patch technology, offering 12-lead ECG capability in the form of a simple patch that is similar in size and shape to existing single-lead ECG patch monitors in the market today," said HeartBeam CEO and Founder Branislav Vajdic.
該專利為我們突破性的心電貼片技術提供了額外的知識產權保護，以簡單貼片的形式提供12導聯心電功能，在大小和形狀上與目前市場上現有的單導聯心電貼片監測器相似。布拉尼斯拉夫·瓦季奇.
"Our 12-lead ECG patch technology offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care and could have a disruptive effect on the ECG patch market with its ischemia detection capability."
我們的12導聯心電貼片技術有可能帶來與當前12導聯心電護理標準一致的診斷準確率，並可能因其缺血檢測能力而對心電貼片市場產生顛覆性影響。“
See Also: Why Is Rhythm Pharmaceuticals Stock Down Today?
另見：Rhythm PharmPharmticals股票今日為何下跌？
According to data from Benzinga Pro, Heartbeam has a 52-week high of $5.47 and a 52-week low of $1.12.
根據Benzinga Pro的數據，HeartBeam的52周高點為5.47美元，52周低點為1.12美元。